Should routine platelet testing be done on all patients undergoing percutaneous coronary intervention?: The Evidence Base for Platelet Function Testing in Patients Undergoing Percutaneous Coronary Intervention

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Circulation. Cardiovascular Interventions

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCINTERVENTIONS.109.928861PMID 20551394
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.

  2010cited by this paper
• Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET study.

  2010cited by this paper
• Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

  2010cited by this paper
• Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.

  2009cited by this paper
• Cytochrome p-450 polymorphisms and response to clopidogrel.

  2009cited by this paper
• Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study

  2009cited by this paper
• Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance

  2009cited by this paper
• Bedside Evaluation of Thienopyridine Antiplatelet Therapy

  2009cited by this paper
• Abstract 5901: The Effect of Ticagrelor in Stable Coronary Artery Disease Patients Nonresponsive to Clopidogrel: The RESPOND Study

  2009cited by this paper
• Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.

  2009cited by this paper
• Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

  2009cited by this paper
• Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.

  2009cited by this paper
• Genetic determinants of response to clopidogrel and cardiovascular events.

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

  2009cited by this paper
• Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up

  2009cited by this paper
• Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

  2009cited by this paper
• Clopidogrel response variability: Current status and future directions

  2009cited by this paper
• Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.

  2008cited by this paper
• Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.

  2008cited by this paper
• Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.

  2008cited by this paper
• A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

  2008cited by this paper
• Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.

  2008cited by this paper
• The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study.

  2008cited by this paper
• Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

  2008cited by this paper
• Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction.

  2008cited by this paper
• Clinical ResearchInterventional CardiologyPoint-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reacti

  2008cited by this paper
• Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.

  2007cited by this paper
• ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome

  2007cited by this paper
• Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D

  2007cited by this paper
• ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie

  2007cited by this paper
• Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study.

  2007cited by this paper
• Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events

  2007cited by this paper
• Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models

  2007cited by this paper
• Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.

  2007cited by this paper
• Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D

  2007cited by this paper
• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.

  2007cited by this paper
• Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

  2007cited by this paper
• Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

  2006cited by this paper
• Platelet function assessment to predict outcomes after coronary interventions: hype or hope?

  2006cited by this paper
• High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

  2006cited by this paper
• Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.

  2006cited by this paper
• Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.

  2006cited by this paper
• Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

  2005cited by this paper
• The difference between clopidogrel responsiveness and posttreatment platelet reactivity.

  2005cited by this paper
• Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction

  2004cited by this paper
• Durability of platelet inhibition by clopidogrel.

  2003cited by this paper
• Structure and stereochemistry of the active metabolite of clopidogrel.

  2002cited by this paper
• Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

  2002cited by this paper
• Bias and causal associations in observational research.

  2002cited by this paper
• EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• American Association of Cardiovascular and Pulmonary Rehabilitation

  1985cited by this paper

• DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan

  2018cites this paper
• Practical Aspects of Monitoring of Antiplatelet Therapy

  2016cites this paper
• Monitoring and Reversal of Anticoagulation and Antiplatelets.

  2013cites this paper
• Long-term antiplatelet therapy: from clinical trials to clinical application

  2012cites this paper
• No Association of ABCB1 C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting

  2012cites this paper
• Incidence and predictors of definite stent thrombosis after coronary stent implantation.

  2012cites this paper
• High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel

  2012cites this paper
• Intervention for Non-ST-Segment Elevation Acute Coronary Syndromes

  2012cites this paper
• Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.

  2011cites this paper
• The brave new world of antiplatelet therapy: seeking clarity in a world of increasing choice and complexity.

  2011cites this paper
• Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial

  2011cites this paper